These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 9515789)

  • 1. Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor.
    Hirata T; Fukuse T; Naiki H; Hitomi S; Wada H
    Cancer Res; 1998 Mar; 58(6):1108-10. PubMed ID: 9515789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance.
    Nguyen VN; Mirejovský T; Melinová L; Mandys V
    Neoplasma; 2000; 47(6):400-8. PubMed ID: 11263866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD44 and its v6 spliced variant in lung tumors: a role in histogenesis?
    Fasano M; Sabatini MT; Wieczorek R; Sidhu G; Goswami S; Jagirdar J
    Cancer; 1997 Jul; 80(1):34-41. PubMed ID: 9210706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced expression of CD44v3 variant isoform is associated with unfavorable outcome in non-small cell lung carcinoma.
    Pirinen R; Hirvikoski P; Böhm J; Kellokoski J; Moisio K; Virén M; Johansson R; Hollmén S; Kosma VM
    Hum Pathol; 2000 Sep; 31(9):1088-95. PubMed ID: 11014576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression of the CD44 variant exon 6 is associated with lymph node metastasis in non-small cell lung cancer.
    Miyoshi T; Kondo K; Hino N; Uyama T; Monden Y
    Clin Cancer Res; 1997 Aug; 3(8):1289-97. PubMed ID: 9815811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD44v6 as a prognostic factor in cervical carcinoma FIGO stage IB.
    Bouda J; Boudova L; Hes O; Havir M; Tempfer C; Kohlberger P; Svoboda T; Rokyta Z; Speiser P
    Anticancer Res; 2005; 25(1B):617-22. PubMed ID: 15816636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma.
    Oyama T; Osaki T; Nose N; Ichiki Y; Inoue M; Imoto H; Yoshimatsu T; Kodate M; Uramoto H; Mizoue T; Yano K; Yasumoto K
    Anticancer Res; 2000; 20(1B):505-10. PubMed ID: 10769714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of immunohistochemically detected CD44 expression in patients with carcinoma of the vulva.
    Tempfer C; Gitsch G; Haeusler G; Reinthaller A; Koelbl H; Kainz C
    Cancer; 1996 Jul; 78(2):273-7. PubMed ID: 8674003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy.
    Noordzij MA; van Steenbrugge GJ; Verkaik NS; Schröder FH; van der Kwast TH
    Clin Cancer Res; 1997 May; 3(5):805-15. PubMed ID: 9815753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of CD44v6-containing isoforms during proliferation of normal and malignant epithelial cells.
    Soukka T; Salmi M; Joensuu H; Häkkinen L; Sointu P; Koulu L; Kalimo K; Klemi P; Grénman R; Jalkanen S
    Cancer Res; 1997 Jun; 57(11):2281-9. PubMed ID: 9187133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered CD44 variant 6 expression in FIGO stage IB cervical carcinoma.
    Ayhan A; Baykal C; Al A; Ayhan A
    Gynecol Oncol; 2001 Dec; 83(3):569-74. PubMed ID: 11733974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic significance of expression of CD44s and CD44v6 isoforms in squamous cell carcinoma of the supraglottic larynx.
    Rodrigo JP; Domínguez F; Alvarez C; González MV; Herrero A; Suárez C
    Am J Clin Pathol; 2002 Jul; 118(1):67-72. PubMed ID: 12109858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of E-cadherin, and CD44s and CD44v6 and its association with prognosis in head and neck cancer.
    Kawano T; Nakamura Y; Yanoma S; Kubota A; Furukawa M; Miyagi Y; Tsukuda M
    Auris Nasus Larynx; 2004 Mar; 31(1):35-41. PubMed ID: 15041052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma.
    Arinaga M; Noguchi T; Takeno S; Chujo M; Miura T; Uchida Y
    Cancer; 2003 Jan; 97(2):457-64. PubMed ID: 12518370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Y-box-binding protein-1 expression is not correlated with p53 expression but with proliferating cell nuclear antigen expression in non-small cell lung cancer.
    Yoshimatsu T; Uramoto H; Oyama T; Yashima Y; Gu C; Morita M; Sugio K; Kohno K; Yasumoto K
    Anticancer Res; 2005; 25(5):3437-43. PubMed ID: 16101161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of CD44v6 in advanced gastric cancer and its relationship to hematogenous metastasis and long-term prognosis.
    Yamaguchi A; Goi T; Yu J; Hirono Y; Ishida M; Iida A; Kimura T; Takeuchi K; Katayama K; Hirose K
    J Surg Oncol; 2002 Apr; 79(4):230-5. PubMed ID: 11920780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers.
    Hommura F; Dosaka-Akita H; Mishina T; Nishi M; Kojima T; Hiroumi H; Ogura S; Shimizu M; Katoh H; Kawakami Y
    Clin Cancer Res; 2000 Oct; 6(10):4073-81. PubMed ID: 11051259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of E-cadherin, beta-catenin, CD44s and CD44v6 in gastric adenocarcinoma: relationship with lymph node metastasis.
    Joo M; Lee HK; Kang YK
    Anticancer Res; 2003; 23(2B):1581-8. PubMed ID: 12820426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of MDA-7/IL-24 and its clinical significance in resected non-small cell lung cancer.
    Ishikawa S; Nakagawa T; Miyahara R; Kawano Y; Takenaka K; Yanagihara K; Otake Y; Katakura H; Wada H; Tanaka F
    Clin Cancer Res; 2005 Feb; 11(3):1198-202. PubMed ID: 15709189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer.
    Imai H; Kaira K; Oriuchi N; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M
    Histopathology; 2009 Jun; 54(7):804-13. PubMed ID: 19635099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.